KNSA Stock Analysis: Buy, Sell, or Hold?
KNSA - Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
$80.79
1.09 (1.37%)
▲
5d:
+1.06%
30d:
+6.19%
90d:
+28.56%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Oct 27, 2026
3d
Get Alerted When KNSA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: KNSA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: KNSA shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$78.75
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$48.90
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: KNSA is currently trading at $80.79, which is considered extended relative to its 30-day fair value range of $75.73 to $79.73. From a valuation perspective, the stock is trading at a premium (Forward PE: 50.0) compared to its historical average (33.6). At these levels, the market is pricing in 14.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, KNSA is in a strong uptrend. Immediate support is located at $76.88, while resistance sits at $84.06.
Market Sentiment: KNSA scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $98.00 (+21.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KNSA is in a strong uptrend. Immediate support is located at $76.88, while resistance sits at $84.06.
Market Sentiment: KNSA scores 37/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $98.00 (+21.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$75.73 -
$79.73
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
41.5%
Protect Your Profits
Holding KNSA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (37/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 21.3% below Wall St target ($98.00)
- NEUTRAL: Trading at premium valuation - market expects 14.1% growth which is achievable
- WARNING: Composite score 48/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$75.73 -
$79.73
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$6.34
(7.8%)
Support & Resistance Levels
Support Level
$76.88
Resistance Level
$84.06
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
49.95
Wall Street Target
$98.00
(+21.3%)
Revenue Growth (YoY)
55.4%
Earnings Growth (YoY)
30.4%
Profit Margin
9.6%
Valuation Premium vs History
+14.1% premium
PE vs Historical
50.0 vs 33.6
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+14.1%
(market-implied from PE analysis)
1-Year Target
$92.18
(+14%)
2-Year Target
$105.18
(+30%)
3-Year Target
$120.01
(+49%)
3-Yr Target (if PE normalizes)
(PE: 50→34)
PE COMPRESSION
$80.73
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 49.9, Growth: 39.7%)
$220.46
(+173%)
Base:
(SPY PE: 19.9, Growth: 39.7%)
$87.66
(+9%)
Bear:
(PE: 16.9, Growth: 39.7%)
$74.51
(-8%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (60x PE), but valuation improves significantly next year (50x PE) as earnings recover.
Forward PE: 59.52 | Forward EPS (Implied): $1.36
Bull Case
$97.55
(+21%)
Analyst growth 15.0%, PE expands to 62.5
Base Case
$80.79
(0%)
Market implied 0.0%, PE stable at 59.5
Bear Case
$61.80
(-24%)
Severe decline -15.0%, PE contracts to 53.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 23, 2026 1:30 AM ET
Data refreshes hourly during market hours. Next update: 2:30 AM
Data refreshes hourly during market hours. Next update: 2:30 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KNSA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 60 HOLD |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 49 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$56 | 43 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 62 BUY |
|
HROW
Harrow Health Inc |
STRONG BUY
9 analysts |
$65 | 59 HOLD |
Advanced KNSA Option Strategies
Professional options setups generated by AI based on today's KNSA price and gamma walls.
